small molecule

INVEGA SUSTENNA

PALIPERIDONE PALMITATE

Loss of exclusivityJanuary 2031latest FDA-listed patent expiry
CompanyJanssen PharmaceuticalsSee this company's full patent-cliff portfolio

Drug detail

Brand nameINVEGA SUSTENNA
Active ingredientPALIPERIDONE PALMITATE
Strength156MG/ML (156MG/ML)
Dosage formSUSPENSION, EXTENDED RELEASE
RouteINTRAMUSCULAR
ModalitySmall molecule
FDA approvalJuly 2009
Marketing statusRX

Listed patents

PatentExpiresType
9439906January 2031use U-2758

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Not found